Alpha Synuclein - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Pipeline Review, H2 2019’, provides in depth analysis on Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology under development targeting Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects

- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab ...

AbbVie Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

Neuropore Therapies Inc

nLife Therapeutics SL

Prevail Therapeutics Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

Seelos Therapeutics Inc

UCB SA

United Neuroscience Ltd

Voyager Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Companies Involved in Therapeutics Development

AbbVie Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

Neuropore Therapies Inc

nLife Therapeutics SL

Prevail Therapeutics Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

Seelos Therapeutics Inc

UCB SA

United Neuroscience Ltd

Voyager Therapeutics Inc

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Drug Profiles

ABBV-0805 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABL-301 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Alpha-Synuclein for Glaucoma – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases and Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANVS-401 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANVS-405 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASOA-19 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1947D – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1948D – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1949D – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950D – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950R – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit SNCA for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinpanemab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Alpha Synuclein for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapies to Inhibit SNCA for Neurology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-82422 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1341 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLFPD-1233 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-088 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-10018A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-189 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-1601 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-1602 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-004 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasinezumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-004 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-007 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Neurodegerative Diseases Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SNCA for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trehalose – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCB-0599 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Product Development Milestones

Featured News & Press Releases

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbbVie Inc, H2 2019

Pipeline by AC Immune SA, H2 2019

Pipeline by AFFiRiS AG, H2 2019

Pipeline by Annovis Bio Inc, H2 2019

Pipeline by Arvinas Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Biogen Inc, H2 2019

Pipeline by Denali Therapeutics Inc, H2 2019

Pipeline by Enterin Inc, H2 2019

Pipeline by Fulcrum Therapeutics Inc, H2 2019

Pipeline by Genmab A/S, H2 2019

Pipeline by ICB International Inc, H2 2019

Pipeline by Neuropore Therapies Inc, H2 2019

Pipeline by nLife Therapeutics SL, H2 2019

Pipeline by Prevail Therapeutics Inc, H2 2019

Pipeline by Priavoid GmbH, H2 2019

Pipeline by ProMIS Neurosciences Inc, H2 2019

Pipeline by Prothena Corp Plc, H2 2019

Pipeline by Seelos Therapeutics Inc, H2 2019

Pipeline by UCB SA, H2 2019

Pipeline by United Neuroscience Ltd, H2 2019

Pipeline by Voyager Therapeutics Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports